Chronic infection with hepatitis B virus (HBV) affects approximately three hundred million people worldwide. Under current international guidelines, most of these people with chronic hepatitis are not eligible for antiviral therapy, because the evidence to expand treatment eligibility to these asymptomatic people living with HBV in Africa is very scarce. [Foroyaa]

More at Foroyaa